T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
Rhea-AI Summary
T2 Biosystems (NASDAQ:TTOO), a company specializing in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results and provide business updates. Investors can access the call via webcast at www.t2biosystems.com or by dialing 877-545-0320 (US/Canada) or 973-528-0002 (International) using passcode 903508.
Positive
- None.
Negative
- None.
News Market Reaction – TTOO
On the day this news was published, TTOO declined 0.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.
Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320 (US/Canada) or 973-528-0002 (International), passcode 903508, approximately ten to five minutes prior to the start time.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2Lyme™ Panel, and the expended T2Candida Panel to add the detection of Candida auris. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When will T2 Biosystems (TTOO) report Q3 2024 earnings?
How can investors join T2 Biosystems (TTOO) Q3 2024 earnings call?
What is the conference call passcode for T2 Biosystems (TTOO) Q3 2024 earnings?
